Results 91 to 100 of about 145,446 (298)

Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation

Кардиоваскулярная терапия и профилактика, 2005
Aim. To study efficacy and safety of propafenone (loading single dose of 600 mg per os) in treating atrial fibrillation (AF) paroxysms. Material and methods. The study included 233 patients with persistent AF, aged 31-62 (mean age 57.6 ± 2.8 years), from
I. G. Fomina, A. I. Tarzimanova, A. V. Vetluzhsky, A. A. Abramova   +3 more
doaj  

Influence of Atrioventricular Nodal Reentrant Tachycardia Ablation on Right to Left Inter-atrial Conduction [PDF]

, 2005
Background: Radiofrequency (RF) catheter ablation is the procedure of choice for the potential cure of atrioventricular nodal reentrant tachycardia (AVNRT) with high success rates.
Eksik, Abdurrahman, Akyol, Ahmet, Norgaz, Tugrul, Erdinler, Izzet   +3 more
core  

Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation:Results of the RACE 3 trial [PDF]

, 2018
Aims: Atrial fibrillation (AF) is a progressive disease. Targeted therapy of underlying conditions refers to interventions aiming to modify risk factors in order to prevent AF. We hypothesised that targeted therapy of underlying conditions improves sinus
Anne H Hobbelt, Bastiaan Geelhoed, Dirk J Van Veldhuisen, Hans L Hillege, Harry J G M Crijns, Isabelle C Van Gelder, Jan G P Tijssen, Johan Brügemann, Marcelle D Smit, Marco Alings, Michiel Rienstra, null null, Raymond Tukkie, Robert G Tieleman   +13 more
core   +2 more sources

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Automatic diagnostics of extrasystoles during cardiointervalogram preliminary assessment (filtration) in systems for heart rate variability analysis

Российский кардиологический журнал, 2005
Heart rate variability analysis requires the following: registered rhythm must be sinus one, regular or arrhythmic; cardiac arrhythmias should be diagnosed automatically and interpoled without disturbing RR interval dynamic row.
O. K. Rybak, N. V. Furman, V. V. Mukhortov, A. P. Burlaka, S. S. Shamtova, E. V. Lazareva, N. P. Ivannikova   +6 more
doaj  

Left atrial function in uraemic patients: Four‐dimensional automatic left atrial quantitative technology study

ESC Heart Failure, Volume 12, Issue 2, Page 1316-1325, April 2025.
Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley   +1 more source

DIGOXIN IN SINUS RHYTHM [PDF]

The Lancet, 1979
M A, Ghouri, R, Railton, K C, Young, J C, Rodger   +3 more
openaire   +3 more sources

Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]

, 2017
No abstract ...
Aspirin Myocardial Infarction Study Research Group, Baigent, Baigent, Bonaca, Chin, Cleland, Cleland, Cleland, Cleland, Cleland, Cleland, Gelder, Homma, Lewis, Massie, Meune, Michel, Pitt, Pitt, Silva, Solomon, Tweeddale, Zannad, Zannad   +23 more
core   +1 more source